Orchestra BioMed Holdings Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | – | – | – | – | |
| – | +32.1% | +22.7% | +29.3% | +7.3% | +6.2% | |
| – | +36.7% | +1,030.1% | +123.4% | +39.2% | +12.8% | |
| – | -82.7% | – | – | – | – | |
| – | – | -117.4% | – | – | – | |
| – | -49.2% | +115.7% | -86.8% | +270.5% | +69.2% | |
| – | -51.7% | -592.6% | – | +22.5% | -305.8% | |
| – | – | – | – | – | – | |
| – | -140.0% | – | -405.3% | – | -100.0% | |
| – | -139.9% | – | -55.2% | -36.9% | +202.8% | |
| – | -196.5% | – | +9.4% | -177.0% | – | |
| – | – | – | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.